The capacity of cirmtuzumab to inhibit Wnt5a-induced ROR1-signaling, which appears active in CLL cells of patients treated with ibrutinib [46], provides rationale for the clinical evaluation of this antibody, alone or in combination with ibrutinib or other targeted therapies, for patients with CLL or other ROR1-expressing malignancies, such as MCL [49]. Here, ROR1 is linked to mantle cell lymphoma.